Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29674589 | 1.00 | NOD1 (0.56) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL27793445 | 1.00 | NOD1 (0.56) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL27793444 | 1.00 | NOD1 (0.56) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL29511099 | 0.95 | FOLH1 (0.57) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL29563714 | 0.95 | FOLH1 (0.57) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL1711244 | 0.95 | FOLH1 (0.57) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL29368554 | 0.95 | FOLH1 (0.57) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL1711242 | 0.95 | FOLH1 (0.57) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL29405941 | 0.93 | FOLH1 (0.55) | NOD1FOLH1GNPATCPB2SLC6A5 | |
| SCHEMBL11644217 | 0.92 | FOLH1 (0.54) | NOD1FOLH1GNPATCPB2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | CTSB, CTSE, CTSV | NOD1 3437/4885FOLH1 36/4885GNPAT 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.